Roche’s Gavreto approved in Europe to treat RET fusion-positive NSCLC
Roche has secured the European Commission (EC) conditional marketing authorisation for Gavreto (pralsetinib) to treat a type of non-small cell lung cancer (NSCLC). The drug was indicated for